Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR
Information source: Lamm, Steven, M.D.
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypogonadism
Intervention: AndroGel (Transdermal Testosterone Gel) (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: Lamm, Steven, M.D. Official(s) and/or principal investigator(s):
Steven Lamm, M.D., Principal Investigator, Affiliation: Unaffiliated
Overall contact:
Steven Lamm, M.D., Phone: 212-988-1146, Email: slamm10@gmail.com
Summary
Low testosterone may be responsible for "soft" erections in men. The purpose of our study is
to see whether the daily application of a testosterone gel to raise testosterone levels will
also increase the "hardness" of a man's erection.
Clinical Details
Official title: Phase I Study of Transdermal Testosterone Gel and Its Effect on Erection Quality as Measured by a Digital Inflection Rigidometer (DIR)
Study design: Cross-Sectional, Defined Population, Prospective Study
Eligibility
Minimum age: 21 Years.
Maximum age: 59 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Testosterone <350 ng/dL,
- 21-59 years of age,
- BMI <30
Exclusion Criteria:
- Those with carcinoma of the breast or known or suspected carcinoma of the prostate or
with known hypersensitivity to any of the ingredients in AndroGel.
- Men will be excluded if they have unstable angina, hypertension, diabetes, heart
failure, or coronary artery disease.
- Men will agree to discontinue use of current testosterone replacement, as well as
Viagra or any other PDE5 inhibitors for 30 days.
Locations and Contacts
Steven Lamm, M.D., Phone: 212-988-1146, Email: slamm10@gmail.com
Steven Lamm, M.D., New York, New York 10028, United States; Recruiting
Steven Lamm, M.D., Phone: 212-988-1146, Email: slamm10@gmail.com
Steven Lamm, M.D., Principal Investigator
Additional Information
Starting date: December 2005
Last updated: January 22, 2007
|
